In the search for novel agents capable of enhancing the effectsof existing anticancer treatments, medicarpin was studied alone andin combination with tumor necrosis factor-related apoptosis-inducingligand (TRAIL) against primary myeloid leukemia cells and primaryhuman peripheral blood mononuclear cells (PBMCs). This evidence concerns the gene TNFSF10 and myeloid leukemia.